Cardiovascular Systems, Inc. CSII has successfully treated the first patient in Europe with its Stealth 360 Peripheral Orbital Atherectomy System (OAS) 1.25 mm Micro Crown with GlideAssist (1.25 Micro Crown). The company has launched the 1.25 Micro Crown in Germany, in partnership with OrbusNeich, a leading provider of cardiovascular solutions.
This is a major achievement for the company toward strengthening its portfolio for the treatment of critical limb ischemia or CLI.
More About the 1.25 Micro Crown
The 1.25 Micro Crown is a minimally-invasive option to efficiently treat CLI by modifying calcified lesions below the knee and resuming blood flow to the foot.
The GlideAssist feature aids the 1.25 Micro Crown to rotate at a tedious speed of 5K rpm, thereby ensuring easier tracking and movement needed to access diffuse, calcified lesions located below the knee. The device’s dual mechanism of action of differential sanding and pulsatile forces will be critical in treating the challenging calcified lesions found below the knee.
Per Zion Market Research, the global CLI treatment market reached a worth of $3.12 billion in 2018 and is anticipated to reach $5.39 billion by 2025, at a CAGR of 8.1%. Hence, this development comes at an ideal time for the company.
Lately, Cardiovascular Systems has been witnessing significant progress with its OAS technology. In 2018, the company had launched OAS in Asia, Europe and the Middle East, in collaboration with its distribution partner, OrbusNeich.
In January 2019, the company treated the first patient in the UAE with its Diamondback 360 Coronary OAS.
In October 2019, the company announced its first successful patient treatment case with the Stealth 360 Peripheral OAS in the UAE.
In the past one year, the company’s shares have outperformed the industry. The stock has rallied 58.9% compared with the industry’s 13.5% rise.
Zacks Rank & Stocks Worth a Look
Cardiovascular Systems carries a Zacks Rank #5 (Strong Sell).
A few better-ranked stocks from the broader medical space are Haemonetics Corporation HAE, NuVasive, Inc NUVA and ResMed RMD. While ResMed sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics has a projected long-term earnings growth rate of 13.5%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate of 12.9%.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardiovascular Systems, Inc. (CSII) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
NuVasive, Inc. (NUVA) : Free Stock Analysis Report
ResMed Inc. (RMD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research